Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06062212

Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

Effect of Transpulmonary Mechanical Power on the Prognosis of Patients With Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Beijing Chao Yang Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers

Summary

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.

Conditions

Interventions

TypeNameDescription
PROCEDURETranspulmonary pressureUse transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.

Timeline

Start date
2023-10-01
Primary completion
2025-12-30
Completion
2025-12-31
First posted
2023-10-02
Last updated
2025-07-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06062212. Inclusion in this directory is not an endorsement.